NCT06477536 Long-Term Safety and Efficacy of HB0034 in Subjects With Generalized Pustular Psoriasis
| NCT ID | NCT06477536 |
| Status | Recruiting |
| Phase | Phase 2, Phase 3 |
| Sponsor | Shanghai Huaota Biopharmaceutical Co., Ltd. |
| Condition | Generalized Pustular Psoriasis |
| Study Type | INTERVENTIONAL |
| Enrollment | 33 participants |
| Start Date | 2024-09-02 |
| Primary Completion | 2025-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 33 participants in total. It began in 2024-09-02 with a primary completion date of 2025-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a Phase IIb, long term extension study to evaluate the safety and efficacy of HB0034 in adult subjects with generalized pustular psoriasis (GPP).
Eligibility Criteria
Inclusion Criteria: * Patients participated in the preceding placebo-controlled Phase 2 study （HB0034-04）and completed at least the Week 12 visit of the HB0034-04 study * Subject must be a candidate for prolonged GPP treatment according to the Investigator's judgment * Men and women of reproductive age who have no parenting plans and are willing to use reliable contraception during the study period and for 6 months after the last dose of the study drug; * Patients who fully understand and voluntarily sign an ICF, and are willing and able to follow clinical study and subsequent visit schedules Exclusion Criteria: * Patients who are experiencing GPP flare
Contact & Investigator
Jianzhong Zhang, PhD
PRINCIPAL INVESTIGATOR
Peking University People's Hospital (PKUPH)
Frequently Asked Questions
Who can join the NCT06477536 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Generalized Pustular Psoriasis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06477536 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06477536 currently recruiting?
Yes, NCT06477536 is actively recruiting participants. Contact the research team at guodong.zhou@huaota.com for enrollment information.
Where is the NCT06477536 trial being conducted?
This trial is being conducted at Beijing, China, Beijing, China, Hangzhou, China.
Who is sponsoring the NCT06477536 clinical trial?
NCT06477536 is sponsored by Shanghai Huaota Biopharmaceutical Co., Ltd.. The principal investigator is Jianzhong Zhang, PhD at Peking University People's Hospital (PKUPH). The trial plans to enroll 33 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.